Market Overview

Analyst: Why The Sucampo Deal Is A Smart Move For Mallinckrodt

Share:
Analyst: Why The Sucampo Deal Is A Smart Move For Mallinckrodt
Related
Jefferies: Reaction In Mallinckrodt Shares To Praxair Competition Overblown
45 Biggest Movers From Yesterday
Mallinckrodt's Stratatech awarded $26M for pediatric studies of StrataFraft skin tissue in thermal burns (Seeking Alpha)
Related SCMP
Barclays: Mallinckrodt's Sucampo Deal Overshadowed By Competitive Threats
Benzinga's Top Upgrades, Downgrades For January 26, 2018

Mallinckrodt PLC (NYSE: MNK) announced an agreement Tuesday to buy Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) for $1.2 billion.

The Analyst

Cantor Fitzgerald analyst Louise Chen has an Overweight on Mallinckrodt with a $42 price target.

The Thesis

The Sucampo transaction is a smart strategic deal, signalling a good end to the year and start to the new one, Chen said. (See the analyst's track record here.) 

"We like this deal because it brings a commercial product (Amitiza) and two Phase 3 pipeline assets (CPP-1X/sulindac, VTS-270) in rare diseases with combined peak sales of $450 million-plus," Chen said.

Mallinckrodt expects the deal to be accretive to 2018 earnings per share by at least 30 cents, and double that in 2019 if it closes in the first quarter of 2018, Chen said. 

The Sucampo deal and others announced by Mallinckrodt earlier this year "expand its portfolio and pipeline assets to diversify the growth and dialogue for the story beyond Acthar," an injectable hormone therapy, Chen said. 

"Concerns about competition and reimbursement challenges for Acthar have been an overhang on MNK's stock, in our opinion," the analyst said. 

Mallinckrodt expects to fund the Sucampo deal through borrowings under its revolving credit facility, a new secured term loan facility and/or cash on hand, according to Cantor Fitzgerald. 

Mallinckrodt suffered from a perception problem that ties it to headline risks in the pharma industry, Chen said, such as scrutiny of high-priced drugs and government investigations. This, the analyst said, masks the growth potential of the company's specialty brands business and its consistent ability to meet or beat expectations.

The Price Action

At the time of publication: 

  • Mallinckrodt shares were up 0.56 percent to $23.45.
  • Sucampo Pharma was rallying 5.74 percent to $17.98.

Related Links:

Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Portola Pharma Shares Under Pressure After FDA Extension

Latest Ratings for MNK

DateFirmActionFromTo
Sep 2018BerenbergInitiates Coverage OnSell
Sep 2018Goldman SachsDowngradesNeutralSell
Aug 2018B. Riley FBRMaintainsNeutralNeutral

View More Analyst Ratings for MNK
View the Latest Analyst Ratings

Posted-In: Analyst Color News Health Care Price Target Reiteration M&A Analyst Ratings General Best of Benzinga

 

Related Articles (SCMP + MNK)

View Comments and Join the Discussion!
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Herman Miller's Tax Prospects Drive Raymond James Upgrade

It's Peak Dating Season: Here Are The Stocks To Flirt With